Crossmark

Utility of Ruxolitinib in a Child with Chronic Mucocutaneous Candidiasis Caused by a Novel STAT1 Gain-of-Function Mutation

Crossref DOI link: https://doi.org/10.1007/s10875-018-0519-6

Published Online: 2018-06-22

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Bloomfield, Markéta https://orcid.org/0000-0001-5330-9341
Kanderová, Veronika

Paračková, Zuzana

Vrabcová, Petra

Svatoň, Michael

Froňková, Eva

Fejtková, Martina

Zachová, Radana

Rataj, Michal

Zentsová, Irena

Milota, Tomáš

Klocperk, Adam

Kalina, Tomáš

Šedivá, Anna
Funding

Funding for this research was provided by:

Ministerstvo Zdravotnictví Ceské Republiky (15-28541A, NV18-05-00162)

Grantová Agentura České Republiky (CZ) (P302/12/G101)

Grantová Agentura, Univerzita Karlova (CZ) (954218)

Grantová Agentura, Univerzita Karlova (460218)

Fakultní nemocnice Motol (00064203)
License Information

Text and Data Mining valid from 2018-06-22
More Information

Article History

Received: 26 December 2017

Accepted: 29 May 2018

First Online: 22 June 2018

Compliance with Ethical Standards

:

: All authors declare that they have no conflicts of interest.